N@N

Market Maker Surveillance Report. AKRX, CRDC, MTEX, BSQR, EXEL, FCEL, Winning Stocks With Lowest Price Friction For Wednesday,

^{Published on 2010-12-15 19:00:32, Last Modified on 2010-12-22 19:49:06 - WOPRAI}
 

December 15, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 1727 companies with "abnormal" market making, 1219 companies with positive Friction Factors and 2676 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. AKORN INC (NASDAQ:AKRX), CARDICA INC (NASDAQ:CRDC), MANNATECH INC (NASDAQ:MTEX), BSQUARE CORP (NASDAQ:BSQR), EXELIXIS INC (NASDAQ:EXEL), FUELCELL ENERGY INC (NASDAQ:FCEL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     AKRX       $0.550       10.29%       1,413,578       54.37%       1,184,212       45.55%       229,366         4,170   
     CRDC       $0.570       17.61%       203,267         55.28%       164,031         44.61%       39,236          688     
     MTEX       $0.180       11.11%       55,931          59.48%       38,098          40.52%       17,833          991     
     BSQR       $1.030       14.84%       491,444         59.11%       331,720         39.90%       159,724         1,551   
     EXEL       $1.000       13.87%       3,006,315       52.02%       2,697,818       46.69%       308,497         3,085   
     FCEL       $0.160       11.23%       3,111,699       51.20%       2,964,981       48.79%       146,718         9,170   

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows FCEL with a dollar gain Wednesday of $0.16000 and a Friction Factor of 9,170 shares. That means that it only took 9,170 more shares of buying than selling to move FCEL higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

AKORN INC (NASDAQ:AKRX) - Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States. The companys Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. The companys Hospital Drugs & Injectables segment markets hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia; and other pharmaceutical products. This segment markets products to hospitals through the wholesale distribution channel. Its Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers. The companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies. It has strategic partnerships with Strides Arcolab Limited; Serum Institute of India, Ltd.; Hameln Pharmaceuticals; and Cipla, Ltd. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.

CARDICA INC (NASDAQ:CRDC) - Cardica, Inc. designs and manufactures medical devices for cardiac and other surgical procedures based on its proprietary stapling and cutting technology. It designs and manufactures its automated anastomosis product line, the C-Port Distal Anastomosis systems and PAS-Port Proximal Anastomosis system to automate the joining of blood vessels for the coronary artery bypass graft (CABG) surgery market. The company develops the C-Port Flex A Anastomosis system to enable automated anastomoses, or the joining of blood vessels, to be performed as part of minimally invasive and surgical robot-facilitated CABG procedures. In addition, Cardica is developing the Microcutter, a true multi-fire endoscopic stapling device designed to be used in a various procedures, including bariatric, thoracic, and general surgery. The company was founded in 1997 and is based in Redwood City, California.

MANNATECH INC (NASDAQ:MTEX) - Mannatech Inc. develops and sells nutritional supplements, topical and skin-care products, and weight-management products. The company sells through a network of independent associates and members in Australia, Britain, Canada, Denmark, Germany, Korea, New Zealand, Taiwan, and the U.S. Mannatech was founded in 1993 and is headquartered in Coppell, Tex.

BSQUARE CORP (NASDAQ:BSQR) - Bsquare Corporation provides software and engineering services to the smart device marketplace primarily in North America and Taiwan. Its proprietary software products include CountDown, a software testing automation tool that provides test solutions to test smart devices; TestQuest Pro, a test automation tool to test embedded systems, including digital entertainment, telecom/datacom, military/aerospace and medical devices, as well as automation systems for industry, retail, offices, buildings, and homes; SDIO Hx that allows small form-factor peripheral and memory cards to be used with smart devices; TI Windows CE BSP for various mobile and embedded device designs; and SchemaBSP, a tool that reduces customer development efforts. The company also offers third-party software products. Its engineering service offerings comprise software and hardware design and development; platform development systems integration; radio interface layer development and testing; application, middleware, and multimedia software development; Adobe Flash Lite Player porting and Flash User Interface development; quality assurance and testing; hardware design, prototype, and product development; device solution strategy consulting; mechanical and ID design; technical support; implementation; and training. The companys customers comprise original equipment manufacturers, original design manufacturers, and enterprises, as well as silicon vendors and peripheral vendors. Bsquare Corporation was founded in 1994 and is headquartered in Bellevue, Washington.

EXELIXIS INC (NASDAQ:EXEL) - Exelixis, Inc. engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer, metabolic, and cardiovascular disorders. The company's compounds primarily target multiple receptor tyrosine kinases simultaneously. Its product candidates include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinositide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company also has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL139 that targets Hedgehog; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, a phase 2 inhibitor of MET and VEGFR2; XL281, a phase 1 product that targets RAF, a cytoplasmic serine/threonine kinase; XL652 and XL041, a phase 1 product for liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Pfizer; and Daiichi Sankyo Company Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

FUELCELL ENERGY INC (NASDAQ:FCEL) - FuelCell Energy, Inc. engages in the development and manufacture of fuel cell power plants for electric power generation primarily in the United States, Canada, Germany, Japan, and South Korea. Its core carbonate fuel cell products include Direct FuelCell or DFC Power Plants for stationary power generation applications. The company also develops carbonate fuel cell and planar solid oxide fuel cell technology. Its proprietary carbonate DFC power plants electrochemically produce electricity directly from readily available hydrocarbon fuels, such as natural gas and biogas fuels. The company serves manufacturers; mission critical institutions, including correction facilities and government installations; and hotels and customers, such as breweries, food processors, and wastewater treatment facilities, who use renewable gas for fuel. FuelCell Energy, Inc. was founded in 1969 and is headquartered in Danbury, Connecticut.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net